Abstract:Nelfinavir is one of several currently available protease inhibitors used to limit viral replication and improve immune function in HIV-infected individuals. It is administered in combination with other antiretroviral agents. Nelfinavir has been evaluated as first-line therapy with nucleoside reverse transcriptase inhibitors (NRTIs) in treatment-naive patients, or as an additional antiretroviral agent in protease inhibitor-naive patients already receiving NRTIs. These studies have shown good efficacy in terms of HIV viral load reduction and increased CD4+ cell counts. When used in combination with NRTIs, nelfinavir 1250 mg twice daily produced similar results to 750 mg 3 times daily. The more convenient twice-daily dosage schedule, which is now approved in the US, may be beneficial in improving patient adherence to therapy. Nelfinavir has also been used successfully in combination with non-nucleoside reverse transcriptase inhibitors and/or other protease inhibitors, with or without NRTIs. Resistance to nelfinavir has been observed in vitro and in clinical isolates from patients experiencing insufficient or waning viral suppression during treatment. Nelfinavir primarily selects for the D30N mutation, which is not seen with other protease inhibitors, and alone does not cause resistance to other protease inhibitors in vitro. Several studies have shown that patients who experience virological failure while receiving nelfinavir can respond to salvage therapy with other protease inhibitors. Diarrhoea is the most frequent adverse event in patients receiving nelfinavir-based combination therapy, but was generally mild and resulted in minimal discontinuation of therapy in clinical trials. Diarrhoea can usually be controlled with drugs that slow gastrointestinal motility. Metabolic disturbances associated with protease inhibitor use (hypercholesterolaemia, hyperglycaemia and lipodystrophy) have also been reported with nelfinavir. Nelfinavir is associated with a number of clinically significant drug interactions and coadministration of some drugs (e.g. astemizole, cisapride, triazolam) is contraindicated. Coadministration of nelfinavir with other protease inhibitors generally resulted in favourable pharmacokinetic interactions (usually increased area under the concentration-time curve for both drugs). Conclusion: Nelfinavir, in combination with reverse transcriptase inhibitors and/or other protease inhibitors, is effective in limiting HIV replication and increasing CD4+ cell counts in HIV-infected adults and children. The convenience of its dosage administration, the low incidence of adverse events, and the potential for salvage therapies indicate that nelfinavir (as part of combined antiretroviral therapy regimens) should be considered as a first-line option in protease inhibitor-naive patients and in those unable to tolerate other protease inhibitors.

[Impairment of IRS-2 Signaling in Rat Insulinoma INS-1 Cells by Nelfinavir].

HIV-1 Protease Inhibitor Nelfinavir Decreases Insulin Secretion from Rat Insulinoma INS-1 Cells

[Effects of Various HIV Protease Inhibitors on Function of Rat Insulinoma Cells].

Nelfinavir, an HIV Protease Inhibitor, Induces Apoptosis and Cell Cycle Arrest in Human Cervical Cancer Cells Via the ROS-dependent Mitochondrial Pathway.

Nelfinavir inhibits human DDI2 and potentiates cytotoxicity of proteasome inhibitors

Inhibition of intracellular hepatitis C virus replication by nelfinavir and synergistic effect with interferon-alpha

Nelfinavir inhibition of Kaposi's sarcoma-associated herpesvirus protein expression and capsid assembly

Nelfinavir: an update on its use in HIV infection

HIV Protease Inhibitor Nelfinavir Targets Human DDI2 and Potentiates Proteasome Inhibitor-based Chemotherapy

Human Immunodeficiency Virus Protease Inhibitors Interact with ATP Binding Cassette Transporter 4/Multidrug Resistance Protein 4: A Basis for Unanticipated Enhanced Cytotoxicity

Inhibition of Adenine Nucleotide Translocator Pore Function and Protection Against Apoptosis in Vivo by an Hiv Protease Inhibitor

Hiv-1 Protease Inhibitors Nelfinavir And Atazanavir Induce Malignant Glioma Death By Triggering Endoplasmic Reticulum Stress

Nelfinavir is Active Against SARS-CoV-2 in Vero E6 Cells

Protease inhibitors used in the treatment of HIV+ induce beta-cell apoptosis via the mitochondrial pathway and compromise insulin secretion.

Antiretrovirals Promote Insulin Resistance in HepG2 Liver Cells through miRNA Regulation and Transcriptional Activation of the NLRP3 Inflammasome

Ritonavir and Lopinavir Suppress RCE1 and CAAX Rab Proteins Sensitizing the Liver to Organelle Stress and Injury

[Preventive Effects of Pioglitazone on Rat Fatty Liver Induced by a High Fat Diet].

[The Expression of Insulin Signal Transduction Molecules and Islet Alpha Cell Insulin Resistance].

Protein Tyrosine Phosphorylation Of The Insulin Receptor And Its Substrate Under Diabetes Mellitus And Nitration Conditions

Inhibition of IRS-1 by hepatitis C virus infection leads to insulin resistance in a PTEN-dependent manner

Differential modulation of P-glycoprotein expression and activity by non-nucleoside HIV-1 reverse transcriptase inhibitors in cell culture